BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/22/2022 6:17:12 AM | Browse: 245 | Download: 443
 |
Received |
|
2021-04-08 15:10 |
|
Peer-Review Started |
|
2021-04-12 00:37 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-08-18 03:51 |
|
Revised |
|
2021-08-31 21:28 |
|
Second Decision |
|
2021-12-29 03:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-12-31 22:29 |
|
Articles in Press |
|
2021-12-31 22:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-17 13:22 |
|
Publish the Manuscript Online |
|
2022-01-22 06:17 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
New approaches for patients with advanced radioiodine-refractory thyroid cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Fabián Pitoia, Fernando Jerkovich, Pierpaolo Trimboli and Anabella Smulever |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fabián Pitoia, MD, PhD, Doctor, Division of Endocrinology, Hospital de Clínicas José de San Martin, University of Buenos Aires, Córdoba 2351, Fifth Floor, Buenos Aires 1120, Argentina. fpitoia@intramed.net |
| Key Words |
Advanced differentiated thyroid cancer; Radioactive iodine refractory thyroid cancer; Multikinase inhibitors; Systemic therapy; Target therapy |
| Core Tip |
The incidence of differentiated thyroid carcinoma has increased due to the rising detection of low-risk small carcinomas. Nevertheless, approximately 10% of patients exhibit advanced disease and two-thirds of the latter will be defined as radioactive iodine (RAI) refractory. After detection, 10-year survival rates are less than 10%, therefore the role of systemic and targeted therapy in these patients has become increasingly relevant in recent years. This review article aims to provide a summary of the current therapeutic strategies in iodine-refractory thyroid cancer, including approved target therapies as well as those for off-label use, RAI resensitization agents, and immunotherapy. |
| Publish Date |
2022-01-22 06:17 |
| Citation |
Pitoia F, Jerkovich F, Trimboli P, Smulever A. New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol 2022; 13(1): 9-27 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i1/9.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i1.9 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
